Patient-Focused Meeting On Vitiligo Could Galvanize R&D As The First Drug Candidates In A Long Time Advance

US FDA meeting directs attention to the vitiligo patient experience as a small group of potential treatments, led by topical Janus kinase inhibitors, are at the Phase II hinge point.

Vitiligo on the hands. Shutterstock 1621981522 — The US FDA continues to solicit patient input as it assembles a Voice of the Patient report for vitiligo, through methods old and new. • Source: Shutterstock

The US Food and Drug Administration’s first patient-focused drug development meeting of 2021 highlighted an undertreated condition, the skin pigmentation disorder vitiligo, that could be on the verge of seeing active new drug development.

With very few late-stage clinical trials of pharmaceutical interventions for vitiligo on record, the patient input from the meeting could help shape and nurture clinical trials in the field –...

Patient-Focused Meeting On Vitiligo Could Galvanize R&D As The First Drug Candidates In A Long Time Advance

More from R&D

More from Pink Sheet